NNC 0560 0004
Alternative Names: NNC-0560-0004Latest Information Update: 30 Aug 2024
At a glance
- Originator Novo Nordisk
- Class Hepatoprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Liver disorders
Most Recent Events
- 04 Jul 2024 Novo Nordisk completes a phase I trial in Liver disorders (In volunteers) in United Kingdom (PO) (NCT06133270)
- 13 Nov 2023 Phase-I clinical trials in Liver disorders (In volunteers) in United Kingdom (PO) (NCT06133270)